Skip to content
  • About Us
    • Careers
  • Services
    • Sell Side Advisory
    • Buy Side Advisory
    • Transaction Planning & Advisory
    • Capital Raising
  • Industry Expertise
    • Business Services
    • Consumer, Food & Retail
    • Healthcare
    • Industrials
    • Plastics & Packaging
    • Software & Technology
  • Transactions
  • Team
  • News & Insights
    • Industry Updates
    • News
    • Perspectives
    • Events
Menu
  • About Us
    • Careers
  • Services
    • Sell Side Advisory
    • Buy Side Advisory
    • Transaction Planning & Advisory
    • Capital Raising
  • Industry Expertise
    • Business Services
    • Consumer, Food & Retail
    • Healthcare
    • Industrials
    • Plastics & Packaging
    • Software & Technology
  • Transactions
  • Team
  • News & Insights
    • Industry Updates
    • News
    • Perspectives
    • Events
Contact

Industry Updates

  • Back to News & Insights

Medical Technology M&A Pulse – Q2 2023

  • August 30, 2023
  • Industry Updates
  • Healthcare, Medical Technology
Q2 2023: Mission “Impossible”: A Soft Landing
  • One year into an unprecedented cycle of interest rate increases, the task of an economic soft landing, once deemed nearly impossible, appears more and more likely. Economists and investors alike doubted the possibility of achieving a soft landing, defined as simultaneously lowering inflation and avoiding a recession. As of the end of Q2 however, inflation appears to be settling while consumers continue to spend, GDP growth persists, and unemployment remains low. This helped drive the Q2 public market rally, bringing the S&P 500 up 16% YTD.
  • Q2 2023 Medical M&A lagged modestly compared to 2022 (152 vs. 168 transactions) but exceeded Q1 2023 by 14 announced transactions. Consumables and Disposables was once again the leading segment, with 24% of all transactions. This was closely followed by Service and Therapeutic Devices, each 22% of all volume.
  • The second quarter represented a welcome rebound for Medical Device public companies after a slow start to the year. The Orthopedic index remained the top performer, finishing the quarter up 19.4%, slightly below the S&P 500 Growth Index of 21.9%. The Diversified Diagnostic index was the laggard of the group, with YTD performance down 1.3%. Companies will look to continue this momentum in the second half of the year, while hopefully seeing a reprieve from early-year macroeconomic headwinds.

 

Read Medical Technology M&A Pulse Q2 2023 Full Report

Download Preview

 

Stay Informed

Subscribe to our newsletter for the latest industry updates

Subscribe

Recent Publications

Packaging M&A Update – July 2023
Plastics M&A Update – July 2023
Medical Technology M&A Pulse – Q2 2023
Human Capital Management M&A Pulse – Q2 2023
Software & Technology M&A Pulse – Q2 2023
Contact

Follow Us On

Cfi Logo White 94x94 On About

Home

  • About
  • Team
  • Careers

Services

  • Sell Side M&A Advisory
  • Buy Side M&A Advisory
  • Capital Raising
  • Transaction Planning & Strategic Advisory

Industry Expertise

  • Business Services
  • Consumer, Food & Retail
  • Healthcare
  • Industrials
  • Plastics & Packaging
  • Software & Technology

News & Insights

  • Transactions
  • News
  • Industry Updates
  • Perspectives

PMCF is a trade name for PMCF Advisors, LLC and P&M Corporate Finance, LLC. The term “PMCF” refers to one or more of these legally separate and independent advisory practices. P&M Corporate Finance, LLC provides capital raising and private placement services that require registration as a broker-dealer.

©2023 PMCF

  • Member SIPC​
  • Member FINRA
  • FINRA Broker Check
  • Business Continuity Plan​
  • Disclaimer​
  • Privacy Policy​
Cookie Notice: This site uses cookies to provide you with a more responsive and personalized service. By using this site you agree to our use of cookies. Please read our Privacy Policy for more information on the cookies we use.AgreePrivacy policy